SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors navigate a combination of bearish short-seller reports and broader macroeconomic concerns. The community remains deeply divided, with some actively accumulating shares during the dip based on insider buying, while others express frustration over persistent share dilution and the stock's failure to maintain momentum alongside the broader market.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility and heavy investor interest following its recent public debut, driven by its specialized focus on AI-driven autonomous drone software already deployed in active combat zones. Market participants are actively debating the stock's potential for a massive short-term run due to its micro-float structure, with discussions polarized between excitement over its defense-tech relevance and skepticism regarding its early-stage revenue and valuation.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing significant volatility ahead of its upcoming earnings report, with the community actively debating whether the recent share price decline presents a compelling buying opportunity or a signal of broader weakness. Investors are closely monitoring how the company's copper and optical interconnect technologies will hold up against evolving hyperscaler demands and competitive pressures from peers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly shares are experiencing volatility as investors react to competitive data in the GLP-1 sector and positive clinical trial readouts for the company's oncology pipeline. While the community remains divided over the sustainability of its premium valuation, bullish sentiment persists around the anticipated regulatory approval of its oral obesity therapy.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently a focal point for investors as it approaches critical mid-year regulatory deadlines, with community discourse heavily influenced by a mix of milestone euphoria surrounding nuclear design approvals and anxiety over the company's pre-revenue financial status. Market participants are intensely debating the stock's volatility ahead of earnings, tracking heavy options activity and insider trading patterns while weighing the company's long-term potential as a power source for AI infrastructure against the reality of its speculative business model.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining attention as investors react to long-term clinical data published in JAMA Neurology, which reinforces the efficacy and durability of Briumvi in treating relapsing multiple sclerosis. The community remains focused on the company's revenue growth trajectory, potential for a buyout, and the strategic impact of its new national awareness campaign.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant volatility and community debate as it pivots toward an autonomous-heavy model, underscored by its acquisition of parking reservation app SpotHero and the launch of 'Uber Autonomous Solutions' to serve robotaxi developers. While investors remain divided over the shift toward asset-heavy infrastructure investments, the stock is drawing attention from analysts and insiders who cite the company's long-term potential, ecosystem dominance, and upcoming global events as key catalysts for growth.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors monitor the upcoming deadline for a potential proxy fight involving major shareholder Shah Capital, while simultaneously tracking key institutional conferences and high short interest. The community is actively debating the impact of upcoming data, the potential for new high-value licensing partnerships, and the stock's positioning against struggling mRNA competitors.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) continues to see massive volatility as investors weigh the rapid adoption of USDC against institutional insider selling and competitive threats in the stablecoin market. The community remains deeply divided, with bulls pointing to growing transaction volumes and strategic partnerships, while vocal bears argue that the stock's recent parabolic rise is a detached, synthetic rally prone to a sharp reversal.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan

Ardelyx (NASDAQ:ARDX) executives outlined commercial momentum for IBSRELA and XPHOZAH, key investment priorities for 2026, and development plans for a chronic idiopathic constipation (CIC) expansion...

Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX

Vanguard Group Inc. grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 14.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving Average - What's Next?

Ardelyx (NASDAQ:ARDX) Stock Price Crosses Below Two Hundred Day Moving Average - Here's What Happened...

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Key PointsMichael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share...

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity...

<ul class="summary-bullets"><li>Director David Mott bought 333,333 shares at a weighted average price of $5.84, lifting his stake to more than 3.3 million shares.</li><li>The insider buy followed a mixed Q4 earnings report in which revenue rose to $125.2 million, beating expectations, while earnings remained flat.</li><li>Ibsrela drove the revenue beat, offsetting softer Xphozah sales, and the company guided for Ibsrela revenue of $410 million to $430 million in 2026.</li></ul>Ardelyx shares jumped more than 5% overnight after a board director made a sizable open-market purchase, adding fuel to growing investor confidence in Ibsrela, the company’s flagship constipation drug.<a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> rose 0.4% on Monday after tumbling 15% on Friday, when the company reported no earnings for the fourth quarter (Q4).<h2 class="st-heading-2">Ardelyx Director Buys 333K Shares In Open Market</h2>According to a new regulatory filing, David Mott, a director at Ardelyx, purchased 333,333 shares of the company’s stock on Friday at a weighted average price of $5.84 per share.The filing shows the purchase was made in multiple open-market transactions, with prices ranging from $5.67 to $6.00. Following the buy, Mott holds over 3.3 million Ardelyx shares.&nbsp;<h2 class="st-heading-2">Ibsrela Drives Q4 Revenue Beat</h2>The insider buy followed Ardelyx’s Q4 earnings report, where revenue rose to $125.2 million, up from $116.1 million a year earlier. The result topped Wall Street expectations of about $119.4 million.The company said the increase was driven largely by higher adoption of Ibsrela, which is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Growth in Ibsrela helped offset softer sales from Xphozah, Ardelyx’s drug for lowering phosphate levels in patients with chronic kidney disease on dialysis.Earnings per share came in at $0.0, compared with $0.02 in the year-ago quarter and slightly below expectations of $0.01.<h2 class="st-heading-2">Strong 2026 Outlook Anchored By Ibsrela</h2>Alongside the results, Ardelyx expects Ibsrela revenue of $410 million to $430 million in 2026, representing growth of at least 50% from 2025 levels. The company cited improvements in prescribing across target healthcare providers, higher patient engagement, and stronger prescription pull-through. For Xphozah, the company forecast 2026 revenue of $110 million to $120 million, up from $103.6 million in 2025.Ardelyx also said it is running additional programs to evaluate Ibsrela in chronic idiopathic constipation and continues to advance its experimental asset RDX10531 across multiple potential indications.<h2 class="st-heading-2">Analysts Reaffirm Bullish Views</h2>On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. Meanwhile, H.C. Wainwright raised its target by 80% to $18 from $10 on Friday, while reiterating a ‘Buy’ rating.H.C. Wainwright said it was encouraged by Ardelyx securing a new U.S. patent extending to November 2042, covering oral formulations of Tenapor, including Ibsrela and Xphozah. Ardelyx has since confirmed that both drugs are now listed in the FDA’s Orange Book, marking a step that strengthens intellectual property protection.CEO Mike Raab previously said the listing was “an important step in extending protections for our portfolio of first-in-class medicines.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for ARDX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rdx_ss_png_9ca239304b.webp" alt="rdx ss.png" width="968" height="140"><figcaption>ARDX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “Maybe retailers will realize now’s the time to buy. Nice buy by mott ”<stembedurl>https://stocktwits.com/mktfixer/message/645684167</stembedurl>Another user said, “Always nice seeing Mr.Mott’s investing in the company. Clearly, he’s in it to win it. He knows what he owns and how the current strategy will be a success. So swell! “<stembedurl>https://stocktwits.com/imlivinit/message/645684336</stembedurl>ARDX stock has declined 1.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Equity

Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells $47,829.60 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura Williams sold 8,176 shares of Ardelyx stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Insider Sells 10,439 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Eric Duane Foster sold 10,439 shares of the firm's stock in a transaction on Friday, February 20th. The stock was sold at an average price of...

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 45,982 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 45,982 shares of the company's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Director Purchases $1,946,664.72 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David Mott purchased 333,333 shares of the business's stock in a transaction dated Friday, February 20th. The shares were purchased at an...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.13	--	--	N/A
Q4 '25	$0.01	$0.00	-100.00%	MISSED
Q3 '25	-$0.06	$0.00	100.00%	BEAT
Q2 '25	-$0.13	-$0.08	39.27%	BEAT
Q1 '25	-$0.11	-$0.17	-51.98%	MISSED

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ARDX News

ARDXArdelyx Inc